Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: RECEPTOR ; CELLS ; ENDOTHELIAL-CELLS ; CELL ; Germany ; human ; PROTEIN ; PROTEINS ; DRUG ; cell line ; LINES ; FAMILY ; tumour ; BINDING ; CELL-LINES ; MEMBER ; MEMBERS ; antibodies ; antibody ; TARGET ; IDENTIFICATION ; PLASMA ; Western-blot ; MEMBRANE ; SPECTROMETRY ; CELL-LINE ; LINE ; PURIFICATION ; SURFACE ; isolation ; AFFINITY ; ARGININE METHYLATION ; BRUSH-BORDER ; CONFORMATIONALLY MODIFIED ALBUMINS ; LUNG-CANCER DETECTION ; METHOTREXATE-ALBUMIN ; TREATED SERUM-ALBUMIN ; CALRETICULIN ; albumin-binding proteins (ABPs) ; heterogeneous nuclear ribonucleoproteins (hnRNP) ; crossl
    Abstract: Since albumin is being developed as a drug carrier to target tumours the search for albumin-binding proteins (ABPs), which play a role in cell surface binding and endocytosis of native and conjugated albumins becomes more and more interesting. We isolated five different proteins from purified plasma membranes from three different human tumour cell lines (CCRF-CEM, MV3 and MCF7) by albumin affinity chromatography and identified them as four members of the heterogeneous nuclear ribonucleoproteins (hnRNP) family and calreticulin by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. Contamination of the plasma membrane preparation by nuclear membranes was excluded with anti-nucleopore antibodies. Western blot analyses of plasma membranes showed ABPs with the same molecular weights as the albumin-affinity isolates. Tryptic digestion of intact cells was used to determine the sidedness of the albumin-binding property, which is oriented to the exterior of the cell. Localisation to the plasma membrane and albumin binding is a novel property of hnRNP. (C) 2003 Elsevier Inc. All rights reserved
    Type of Publication: Journal article published
    PubMed ID: 14757165
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...